|
證券時報e公司訊，鋅金屬量376.28萬噸、錫金屬量64.64萬噸、2023年實現營業收入約423.59億元，公司各種金屬保有資源儲量情況：礦石量2.61億噸，銅金屬量1 |
光算谷歌推广光算谷歌seo光算谷歌seo代运营光算谷歌营销光算爬虫池光算爬虫池光算蜘蛛池光算爬虫池光算谷歌外鏈光算谷歌营销光算谷歌推广https://synapse.patsnap.com/drug/918f46815c0b4d67a775ad55c288587dhttps://synapse.patsnap.com/drug/440de5e040523342906812f6ab576353https://synapse.patsnap.com/drug/338c400e01444d668036eb0f7591c5b1https://synapse.patsnap.com/drug/c6b30c219e0b40a88ddb222736a6f9a9https://synapse.patsnap.com/drug/331cd7db377f422b88256935c1698d69https://synapse.patsnap.com/article/what-is-tafluprost-used-forhttps://synapse.patsnap.com/drug/96c35ff88eb145e0a41a3f2b4af456e5https://synapse.patsnap.com/article/what-is-the-mechanism-of-brexucabtagene-autoleucelhttps://synapse.patsnap.com/article/what-are-the-current-trends-in-covid-19-treatment-research-and-developmenthttps://synapse.patsnap.com/article/advancements-in-cancer-therapy-targeting-lsd1-and-hdac68-with-dual-inhibitorshttps://synapse.patsnap.com/drug/c51c35f118794a0097d50010b404fa48https://synapse.patsnap.com/article/anbogen-therapeutics-completes-a%252B-round-financing-for-abt-301-phase-ii-trialhttps://synapse.patsnap.com/drug/0fc3fa15d38e4444b277174b7a5e22ffhttps://synapse.patsnap.com/drug/af3e9a452ab4422f80e873cfc3057187https://synapse.patsnap.com/drug/d4c2847b604e465797dcd80dcaf75e43https://synapse.patsnap.com/article/kymera-initiates-first-patient-dosing-in-phase-1b-atopic-dermatitis-trial-of-kt-621https://synapse.patsnap.com/article/targeting-cancer-with-a-novel-humanized-ror1-x-cd3-dart-molecule-a-promising-therapeutic-approach-for-solid-and-liquid-tumorshttps://synapse.patsnap.com/article/what-is-triamcinolone-acetonide-used-forhttps://synapse.patsnap.com/article/the-patent-landscape-of-ritonavirnirmatrelvirhttps://synapse.patsnap.com/article/what-is-pretomanid-used-forhttps://synapse.patsnap.com/drug/bf6f59beb9d14cdba4c384f85a72110fhttps://synapse.patsnap.com/drug/5972a47b3ec44a5b8b1f807c8df24ce8https://synapse.patsnap.com/article/what-is-oxytetracyc-used-forhttps://synapse.patsnap.com/drug/d1cb471ab6124395a6836a9925fc3171https://synapse.patsnap.com/drug/d75735c10680493988139a42c59ccecchttps://synapse.patsnap.com/drug/f7da42d5b88ac7b0db3fa8b564997db2https://synapse.patsnap.com/article/brenzavvy%25C2%25AE-demonstrates-non-inferiority-to-dapagliflozin-in-chinese-type-2-diabetes-patientshttps://synapse.patsnap.com/blog/the-first-patient-of-vincerx-pharmas-phase-1-clinical-tria-of-vip943-has-been-administeredhttps://synapse.patsnap.com/article/what-is-the-mechanism-of-difemerine-hydrochloridehttps://synapse.patsnap.com/article/what-is-ketoconazole-used-for